News

Published on 18 Mar 2024 on GuruFocus.com via Yahoo Finance

Insider Sell: SVP, Chief Commercial Officer Christian Nichols Sells Shares of Alkermes PLC (ALKS)


Article preview image

Alkermes PLC (NASDAQ:ALKS), a global biopharmaceutical company, is focused on developing innovative medicines that address unmet needs in the fields of neuroscience and oncology. The company's portfolio includes commercial products and a pipeline of product candidates designed to make a meaningful difference in the lives of patients affected by serious mental illness, addiction, and cancer.According to a recent SEC Filing, Christian Nichols, the Senior Vice President and Chief Commercial Officer of Alkermes PLC, sold 10,417 shares of the company on March 18, 2024. The transaction was executed at an average price, resulting in a total value of the sold shares.Over the past year, Christian Nichols has sold a total of 37,551 shares of Alkermes PLC and has not made any share purchases. This latest transaction continues the trend of insider selling activity at the company.

Insider Sell: SVP, Chief Commercial Officer Christian Nichols Sells Shares of Alkermes PLC (ALKS)Insider Sell: SVP, Chief Commercial Officer Christian Nichols Sells Shares of Alkermes PLC (ALKS)

The insider transaction history for Alkermes PLC indicates that there have been no insider buys and 7 insider sells over the past year.On the valuation front, shares of Alkermes PLC were trading at $28.1 on the day of the insider's recent sale, giving the company a market cap of $4.599 billion. The price-earnings ratio stands at 13.30, which is lower than the industry median of 22.46 and also below the company's historical median price-earnings ratio.

NASDAQ.ALKS price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Alkermes PLC (ALKS) Q3 2024 Earnings Report Preview: What to Expect

Alkermes PLC (NASDAQ:ALKS) is set to release its Q3 2024 earnings on Oct 24, 2024. The consensus...

GuruFocus.com · via Yahoo Finance 23 Oct 2024

Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?

Alkermes plc ALKS has made steady progress with its portfolio of proprietary products — Vivitrol ...

Zacks via Yahoo Finance 22 Apr 2024

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

For new and old investors, taking full advantage of the stock market and investing with confidenc...

Zacks via Yahoo Finance 16 Apr 2024

Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study

Alkermes plc ALKS announced positive top-line data from a phase Ib study evaluating its novel, in...

Zacks via Yahoo Finance 11 Apr 2024

Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term

For new and old investors, taking full advantage of the stock market and investing with confidenc...

Zacks via Yahoo Finance 10 Apr 2024

Alkermes stock gains on sleeping disorder drug (NASDAQ:ALKS)

Alkermes (ALKS) stock gains on positive Phase 1b trial results for the company's oral sleeping...

Seeking Alpha 9 Apr 2024

Alkermes' sleep drug shows promise in early trial By Investing.com

Alkermes plc (NASDAQ:ALKS) announced promising results from a phase 1b study of its investigation...

Investing.com 9 Apr 2024

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

For new and old investors, taking full advantage of the stock market and investing with confidenc...

Zacks via Yahoo Finance 25 Mar 2024

Insider Sell: SVP, Chief Commercial Officer Christian Nichols Sells Shares of Alkermes PLC (ALKS)

Alkermes PLC (NASDAQ:ALKS), a global biopharmaceutical company, is focused on developing innovati...

GuruFocus.com via Yahoo Finance 18 Mar 2024

Alkermes plc (NASDAQ:ALKS) Q4 2023 Earnings Call Transcript

Alkermes plc (NASDAQ:ALKS) Q4 2023 Earnings Call Transcript February 15, 2024 Alkermes plc misses...

Insider Monkey via Yahoo Finance 16 Feb 2024